Pacific Biosciences Of California (PACB) Amortizatization of Intangibles (2018 - 2026)
Pacific Biosciences Of California (PACB) recorded quarterly Amortizatization of Intangibles of $1.0 million in Q1 2026, up 100.28% quarter-over-quarter from -$364.1 million in Q4 2025, and down 40.21% on a YoY basis from $1.7 million in Q1 2025.
Pacific Biosciences Of California (PACB) Amortizatization of Intangibles (2018 - 2026) Analysis & Trends
Pacific Biosciences Of California's Amortizatization of Intangibles history runs 9 years deep, the most recent figure standing at $1.0 million for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 40.21% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at -$361.4 million (down 3122.06% YoY), while the FY2025 annual figure was $4.4 million, down 66.54% from the prior year.
- Amortizatization of Intangibles was $1.0 million for Q1 2026 at Pacific Biosciences Of California, up from -$364.1 million in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $5.4 million in Q4 2023 to a low of -$364.1 million in Q4 2025.
- Historically, Amortizatization of Intangibles has averaged -$19.9 million across 5 years, with a median of $1.3 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Amortizatization of Intangibles surged 497.93% in 2024, then plunged 15390.38% in 2025.
- A 5-year view of Amortizatization of Intangibles shows it stood at $1.3 million in 2022, then soared by 311.42% to $5.4 million in 2023, then tumbled by 55.92% to $2.4 million in 2024, then slumped by 15390.38% to -$364.1 million in 2025, then soared by 100.28% to $1.0 million in 2026.
- The last three Amortizatization of Intangibles figures came in at $1.0 million (Q1 2026), -$364.1 million (Q4 2025), and $833000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | 422.00 Mn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 180.00 Mn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | 6.50 Mn |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | 75.00 Mn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | - |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | - |
| 10 | Pacific Biosciences Of California | 402.15 Mn | 126.19 Mn | 12.84 Mn | 1.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.02 Mn |
| Mar 31, 2026 | 1.02 Mn |
| Dec 31, 2025 | -364.06 Mn |
| Dec 31, 2025 | -364.06 Mn |
| Sep 30, 2025 | 833,000.00 |
| Sep 30, 2025 | 833,000.00 |
| Jun 30, 2025 | 833,000.00 |
| Jun 30, 2025 | 833,000.00 |
| Mar 31, 2025 | 1.71 Mn |
| Mar 31, 2025 | 1.71 Mn |
| Dec 31, 2024 | 2.38 Mn |
| Dec 31, 2024 | 2.38 Mn |
| Sep 30, 2024 | 3.65 Mn |
| Sep 30, 2024 | 3.65 Mn |
| Jun 30, 2024 | 4.22 Mn |
| Jun 30, 2024 | 4.22 Mn |
| Mar 31, 2024 | 4.03 Mn |
| Mar 31, 2024 | 4.03 Mn |
| Dec 31, 2023 | 5.40 Mn |
| Dec 31, 2023 | 5.40 Mn |